Skip Nav Destination
Article navigation
Volume 70, Issue Supplement_1
1 June 2021
- Previous Article
- Next Article
P: Clinical Therapeutics / New Technology—Other Therapeutic Agents| June 01 2021
MARTA CLENDENIN;
MARTA CLENDENIN
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
KENNETH KUPFER;
KENNETH KUPFER
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
KYLE S. FORTNER;
KYLE S. FORTNER
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
RANDIE R. LITTLE;
RANDIE R. LITTLE
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
TIMOTHY S. BAILEY;
TIMOTHY S. BAILEY
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
KRISTIN N. CASTORINO;
KRISTIN N. CASTORINO
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
DOUGLAS S. DENHAM;
DOUGLAS S. DENHAM
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
EDWARD KERWIN;
EDWARD KERWIN
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
MARC MICKIEWICZ;
MARC MICKIEWICZ
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
AMY J. NATION;
AMY J. NATION
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
RICHARD C. SAN GEORGE
RICHARD C. SAN GEORGE
San Diego, CA, Columbia, MO, Escondido, CA, Santa Barbara, CA, San Antonio, TX, Medford, OR, Nashville, TN, Oviedo, FL, Carlsbad, CA
Search for other works by this author on:
This Site
Diabetes 2021;70(Supplement_1):750-P
- Split-Screen
- Views Icon Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
- Peer Review
Cite Icon Cite
Citation
MARTA CLENDENIN, KENNETH KUPFER, KYLE S. FORTNER, RANDIE R. LITTLE, TIMOTHY S. BAILEY, KRISTIN N. CASTORINO, DOUGLAS S. DENHAM, EDWARD KERWIN, MARC MICKIEWICZ, AMY J. NATION, RICHARD C. SAN GEORGE; 750-P: Afinion HbA1c Dx Point-of-Care Test Is Accurate to Diagnose Diabetes in CLIA-Waived Settings. Diabetes 1 June 2021; 70 (Supplement_1): 750–P. https://doi.org/10.2337/db21-750-P
Download citation file:
- Ris (Zotero)
- Reference Manager
- EasyBib
- Bookends
- Mendeley
- Papers
- EndNote
- RefWorks
- BibTex
No point of care HbA1c (A1c) assays are CLIA waived for use in diagnosing diabetes. The accuracy of the Abbott Afinion HbA1c Dx (Afinion) was evaluated for this purpose. Operators with no laboratory training (N=21) tested fingerstick (FS) and venous (V) whole blood samples from subjects at 7 CLIA waived sites with 2 Afinion analyzer models (AS100 and Afinion 2). Operators self-trained on use of the Afinion using only materials that are provided when the test is purchased. A portion of each subject’s V sample was tested with a recognized comparative method (CM) at an NGSP Secondary Reference Laboratory (SRL). Consistent with FDA requirements for total error of A1c test systems, the percentage of Afinion results within an Allowable Total Error (ATE) zone of ±6% of the CM result was calculated, as well as the bias at 6.5% A1c. A total of 1,229 subjects with A1c values spanning the Afinion assay measuring range were enrolled. For the Afinion 2, 95.04% (95% lower confidence limit, LCL: 93.33%) of FS and 94.86% (95% LCL: 93.12%) of V results were within the ATE zone. For the AS100, 94.22% (95% LCL: 92.38%) and 93.36% (95% LCL: 91.41%) of Afinion results were within the ATE zone for FS and V samples, respectively. The bias at 6.5% A1c for the Afinion 2 was -0.13% (-0.008% A1c units) for FS and 0.01% (0.000% A1c units) for V samples. For the AS100, the bias was 0.62% (0.040% A1c units) and 1.13% (0.073% A1c units) for FS and V samples, respectively. No operator effects and no differences between the Afinion and CM results that could potentially impact clinical decision making were observed in this study. In subjects with unreported hemoglobin variants (detected by CM), 16/16 FS and 15/16 V Afinion results were within the ATE zone when compared to a second NGSP certified method at the same SRL. These data support the use of Afinion in CLIA waived settings to diagnose diabetes.
Disclosure
M. Clendenin: Employee; Self; Abbott. A. J. Nation: None. R. C. San george: Other Relationship; Self; Abbott. K. Kupfer: Employee; Self; Abbott. K. S. Fortner: Employee; Self; Abbott. R. R. Little: None. T. S. Bailey: Consultant; Self; Abbott Diabetes, LifeScan, Novo Nordisk, Sanofi, Research Support; Self; Abbott, Abbott Diabetes, Biolinq, Capillary Biomedical, Inc., Dexcom, Inc., Eli Lilly and Company, Kowa Research Institute, Inc., Lexicon Pharmaceuticals, Inc., Livongo, Medtronic, Medtrum Technologies, Novo Nordisk, REMD Biotherapeutics, Sanofi, Sanvita, Viacyte, Inc., vTv Therapeutics, Zealand Pharma A/S, Speaker’s Bureau; Self; BD, Medtronic, Sanofi. K. N. Castorino: Consultant; Self; Dexcom, Inc., Research Support; Self; Abbott Diabetes, Abbott Laboratories, Dexcom, Inc., Drawbridge Health, Inc., Lilly Diabetes, Medtronic, Novo Nordisk Inc. D. S. Denham: None. E. Kerwin: Consultant; Self; Amphastar, AstraZeneca, Connect Biopharma, GlaxoSmithKline plc., Mylan N. V., Novartis Pharmaceuticals Corporation, Sunovion Pharmaceuticals Inc., Theravance Biopharma, Speaker’s Bureau; Self; Chiesi USA, Inc. M. Mickiewicz: None.
© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
806 Views
View Metrics
Email alerts
Article Activity Alert
Online Ahead of Print Alert
Latest Issue Alert
Close Modal
- Most Read
- Most Cited
MRI Metrics of Cerebral Endothelial Cell–Derived Exosomes for the Treatment of Cognitive Dysfunction Induced in Aging Rats Subjected to Type 2 Diabetes
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel
Tracking the Recruitment of Diabetogenic CD8+ T-Cells to the Pancreas in Real Time
Elevated First-Trimester Neutrophil Count Is Closely Associated With the Development of Maternal Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes
Circulating CXCR5+PD-1+ICOS+ Follicular T Helper Cells Are Increased Close to the Diagnosis of Type 1 Diabetes in Children With Multiple Autoantibodies